Skip to content
drillr.ai
Sign up

01801.HK

Innovent Biologics, Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 102.40
−0.19%
Ask drillr

  • Aug 27, 2026, 03:50 UTC

    Innovent Biologics reported interim results for the period, with net profit up 50.2% year-on-year and adjusted net profit up 40.5% year-on-year, both significantly beating market expectations.

    Source:

  • Aug 25, 2026, 10:20 UTC

    Innovent Biologics announced its interim results for the six months ended June 2026, with net profit up 50.2% to RMB 1.253 billion.

    Source:

  • Aug 21, 2026, 06:26 UTC

    Innovent Biologics (Suzhou) and Suzhou state-owned capital, among others, established a venture capital partnership, Suzhou Xinhe Guoqing Phase II Venture Capital Partnership (Limited Partnership), with a capital contribution of 185 million yuan.

    Source:

  • Aug 20, 2026, 23:59 UTC

    Hacker group FulcrumSec leaked 1.2 terabytes of data stolen from Danish pharmaceutical company Novo Nordisk on the open internet on 12 August 2026, following an earlier sample leak on 17 July 2026.

    Source:

  • Aug 19, 2026, 04:52 UTC

    Morgan Stanley downgraded Baidu's rating to 'Underweight' and cut its target price to $80, citing accelerating AI investment.

    Source:

  • Aug 14, 2026, 05:54 UTC

    Innovent Biologics, in partnership with Meituan's pharmacy service, launched a new 2mg single-vial formulation of Mazdutide at the 2026 West China Health Industry Conference in Boao, Hainan, exploring instant retail.

    Source:

  • Aug 10, 2026, 01:55 UTC

    Innovent Biologics and Daiichi Sankyo entered an exclusive agreement granting Innovent sole commercialization rights for Vanflyta (quizartinib) in China, with Daiichi Sankyo handling development, manufacturing, and supply.

    Source:

  • Aug 6, 2026, 00:21 UTC

    Innovent Biologics announced that the first subject has been dosed in the third pivotal registration clinical Phase III study of IBI363/TAK-928 combined with bevacizumab for the treatment of advanced colorectal cancer.

    Source:

  • Aug 5, 2026, 00:50 UTC

    Innovent Biologics reached a commercialization partnership with Eli Lilly for the drug Verzenio (abemaciclib) in China, strategically expanding into the breast cancer treatment field.

    Source:

  • Aug 5, 2026, 00:06 UTC

    Innovent Biologics announced that its product revenue for the first half of 2026 exceeded 8.2 billion RMB, up over 55% year-on-year, with second-quarter product revenue exceeding 4.3 billion RMB, up about 60% year-on-year.

    Source:

  • Jul 14, 2026, 00:00 UTC

    Spero Therapeutics signed a cross-exclusive territory license agreement with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. for CD40L-targeting compounds including SP001 (IBI355).

    Source:

  • Jun 30, 2026, 04:00 UTC

    Innovent Biologics and Eli Lilly entered into a distribution and promotion agreement for Verzenios (abemaciclib) in mainland China.

    Source:

  • Jun 29, 2026, 05:20 UTC

    Pfizer's Ecnoglutide and Innovent Biologics' mazdutide injection passed a preliminary review by China's National Healthcare Security Administration for potential inclusion in the basic medical insurance drug catalogue.

    Source: